MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Zhang, Hanwen ^a,c   Wang, Qiuyu ^b   Zhao, Qian ^b   Di, Wen ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Shanghai Key Laboratory of Gynecologic Oncology   (China)

Author keywords

Epithelial ovarian cancer; Invasion; Migration; miR 124; SphK1

Indexed keywords

MICRORNA; MICRORNA 124; SPHINGOSINE KINASE 1;

ADULT; APOPTOSIS; ARTICLE; ASSAY; CANCER CELL; CELL INVASION; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUCIFERASE ASSAY; METASTASIS; MIDDLE AGED; OVARIAN CANCER CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84888181300     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-84     Document Type: Article

References (38)

1. A parsimonious model for gene regulation by miRNAs. Djuranovic S, Nahvi A, Green R, Science 2011 331 550 553 10.1126/science.1191138 21292970
2. MicroRNA signatures in human ovarian cancer. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al. Cancer Res 2007 67 8699 8707 10.1158/0008-5472.CAN-07-1936 17875710 (Pubitemid 47437445)
3. Epigenetics and genetics MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Kasinski AL, Slack FJ, Nature reviews Cancer 2011 11 849 864 10.1038/nrc3166 22113163
4. MicroRNAs in cancer: small molecules with a huge impact. Iorio MV, Croce CM, Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2009 27 5848 5856 10.1200/JCO.2009.24.0317 19884536
5. MicroRNAs in human cancer. Farazi TA, Hoell JI, Morozov P, Tuschl T, Adv Exp Med Biol 2013 774 1 20 23377965
6. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC, Pellegrini P, et al. Proc Natl Acad Sci U S A 2013 110 9845 9850 10.1073/pnas.1305472110 23697367
7. MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. Aigner A, Journal of molecular medicine 2011 89 445 457 10.1007/s00109-010-0716-0 21234533
8. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J, Carcinogenesis 2010 31 766 776 10.1093/carcin/bgp250 19843643
9. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. Zaman MS, Maher DM, Khan S, Jaggi M, Chauhan SC, Journal of ovarian research 2012 5 44 10.1186/1757-2215-5-44 23237306
10. The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. Di Leva G, Croce CM, Frontiers in oncology 2013 3 153 23785667
11. Current status of gynecological cancer in China. Kim K, Zang R, Choi SC, Ryu SY, Kim JW, Journal of gynecologic oncology 2009 20 72 76 10.3802/jgo.2009.20.2.72 19590717
12. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HYS, Pecorelli S, Beller U, Int J Gynecol Obstet 2006 95 161 S192
13. Ovarian Cancer Incidence. Stewart SL, Ovarian Cancer I, Current and Comprehensive Statistics, Ovarian Cancer -Clinical and Therapeutic Perspectives, Samir F, 2012 338 Available from: http://www.intechopen.com/books/ovarian- cancer-clinical-and-therapeutic-perspectives/ovarian-cancer-incidence-current- and-comprehensive-statistics ISBN: 978-953-307-810-6, InTech
14. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, et al. Proc Natl Acad Sci U S A 2008 105 7004 7009 10.1073/pnas.0801615105 18458333 (Pubitemid 351754520)
15. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S, The international journal of biochemistry & cell biology 2010 42 1262 1272 10.1016/j.biocel.2009.12.017 20035894
16. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA, Mutat Res 2011 717 77 84 10.1016/j.mrfmmm.2011.03.008 21420983
17. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Makeyev EV, Zhang J, Carrasco MA, Maniatis T, Mol Cell 2007 27 435 448 10.1016/j.molcel.2007.07.015 17679093 (Pubitemid 47126944)
18. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James D, Costello JF, et al. BMC Med 2008 6 14 10.1186/1741-7015-6-14 18577219 (Pubitemid 352003733)
19. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ, Devere White RW, Oncogene 2013 32 4130 4138 10.1038/onc.2012.425 23069658
20. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z, Liu L, Oncogene 2013 1 11
21. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Zheng F, Liao YJ, Cai MY, Liu Y-H, Liu T-H, Chen S-P, Bian X-W, Guan X-Y, Lin MC, Zeng Y-X, et al. Gut 2012 61 278 289 10.1136/gut.2011.239145 21672940
22. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Liang YJ, Wang QY, Zhou CX, Yin Q-Q, He M, Yu X-T, Cao D-X, Chen G-Q, He J-R, Zhao Q, Carcinogenesis 2013 34 713 722 10.1093/carcin/bgs383 23250910
23. miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. Xia J, Wu Z, Yu C, He W, Zheng H, He Y, Jian W, Chen L, Zhang L, Li W, J Pathol 2012 227 470 480 10.1002/path.4030 22450659
24. Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Milstien S, Spiegel S, Cancer Cell 2006 9 148 150 10.1016/j.ccr.2006.02.025 16530698 (Pubitemid 43357940)
25. Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Fuereder T, Hoeflmayer D, Jaeger-Lansky A, Rasin-Streden D, Strommer S, Fisker N, Hansen B, Crevenna R, Wacheck V, Anticancer Drugs 2011 22 245 252 10.1097/CAD.0b013e328340bd95 21360847
26. Targeting sphingosine kinase-1 to inhibit melanoma. Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP, Pigment Cell Melanoma Res 2012 25 259 274 10.1111/j.1755-148X.2012.00970.x 22236408
27. An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. Pan J, Tao YF, Zhou Z, Cao BR, Wu S-Y, Zhang Y-L, Hu S-Y, Zhao W-L, Wang J, Lou G-L, et al. Journal of translational medicine 2011 9 157 10.1186/1479-5876-9-157 21936950
28. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. Sarkar S, Maceyka M, Hait NC, Paugh SW, Sankala H, Milstien S, Spiegel S, FEBS Lett 2005 579 5313 5317 10.1016/j.febslet.2005.08.055 16194537 (Pubitemid 41395149)
29. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang S, Liu L, Chen T, Li J, Tu H, He X, Liver Int 2012 32 331 338 10.1111/j.1478-3231.2011.02666.x 22098666
30. Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. SH X, LJ Q, HZ N, XB N, CH Z, G Z, WF D, YL G, J Exp Clin Cancer Res 1999 18 233 239 10464713
31. Metformin inhibits the development and metastasis of ovarian cancer. Wu B, Li S, Sheng L, Zhu J, Gu L, Shen H, La D, Hambly BD, Bao S, Di W, Oncol Rep 2012 28 903 908 22752027
32. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, et al. Cancer Cell 2013 23 186 199 10.1016/j.ccr.2012.12.020 23410973
33. Identification of ovarian cancer metastatic miRNAs. Vang S, Wu HT, Fischer A, Miller DH, MacLaughlan S, Douglass E, Steinhoff M, Collins C, Smith PJS, Brard L, Brodsky AS, PLoS One 2013 8 58226 10.1371/journal.pone.0058226 23554878
34. Hallmarks of cancer: the next generation. Hanahan D, Weinberg RA, Cell 2011 144 646 674 10.1016/j.cell.2011.02.013 21376230
35. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Yeh YM, Chuang CM, Chao KC, Wang LH, Int J Cancer 2013 133 867 878 10.1002/ijc.28086 23389731
36. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJ, Steenbergen RD, Mol Cancer 2010 9 167 10.1186/1476-4598-9-167 20579385
37. Targeting microRNAs in cancer: rationale, strategies and challenges. Garzon R, Marcucci G, Croce CM, Nature reviews Drug discovery 2010 9 775 789 10.1038/nrd3179 20885409
38. miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Fowler A, Thomson D, Giles K, Maleki S, Mreich E, Wheeler H, Leedman P, Michael B, Cook R, Little N, et al. Eur J Cancer 2011 47 953 963 10.1016/j.ejca.2010.11.026 21196113